XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 33 filers reported holding XILIO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $461,468 | -19.5% | 218,705 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $573,007 | -17.6% | 218,705 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $695,482 | +18.2% | 218,705 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $588,316 | -7.5% | 218,705 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $636,000 | -0.5% | 218,705 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $639,000 | -58.7% | 218,705 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $1,546,000 | -55.8% | 218,705 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $3,499,000 | – | 218,705 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $4,209,000 | 6.19% |
| AJU IB Investment Co., Ltd. | 667,742 | $1,950,000 | 3.78% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $8,057,000 | 1.35% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $8,192,000 | 0.96% |
| Soleus Capital Management, L.P. | 453,660 | $1,325,000 | 0.21% |
| HARVARD MANAGEMENT CO INC | 416,059 | $1,215,000 | 0.14% |
| RA Capital Management | 1,649,711 | $4,817,000 | 0.13% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,078,692 | $6,070,000 | 0.12% |
| Rock Springs Capital Management LP | 1,362,878 | $3,980,000 | 0.12% |
| Artal Group S.A. | 450,000 | $1,314,000 | 0.07% |